patrys-logo-for-Mobile

Company Highlights

Patrys to initiate clinical trial with Onyx Pharmaceuticals

Patrys to initiate clinical trial with Onyx Pharmaceuticals

In November 2013, Patrys announced it would initiate an Investigator-sponsored clinical trial using PAT-SM6 in combination with Onyx Pharmaceuticals' carfilzomib.

Successful PAT-SM6 Phase I/IIa clinical trial in multiple myeloma

Successful PAT-SM6 Phase I/IIa clinical trial in multiple myeloma

In March 2014, Patrys announced the final results from its Phase I/IIa clinical trial in multiple myeloma with anti-cancer drug PAT-SM6 at The University Hospital of Würzburg.

Peer reviewed publications support PAT-SM6 as an anti-cancer treatment

Peer reviewed publications support PAT-SM6 as an anti-cancer treatment

Patrys has recently focussed on submitting manuscripts to peer reviewed scientific publications in an effort to promote its products, technologies and platform which has not previously been done

PAT-SC1 gastric cancer clinical trial 10-year follow up data published

PAT-SC1 gastric cancer clinical trial 10-year follow up data published

In January 2014, Patrys announced the publication of a new scientific article in Oncology Reports regarding positive results from a follow-up of gastric cancer patients who were treated with anti-cancer compound PAT-SC1.

Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Welcome to Patrys

Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB).  Our principal focus is on the development of a completely new type of product for the treatment of cancer – natural human antibodies.  These natural human antibodies offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.

patrys-cancer-antibodies

Audio Gallery

text_brrwebcasts
Patrys CEO talks
on Boardroom Radio

Listen online

Ross Greenwood
from Money News

Listen online

Search Patrys

config

Follow Us on Media

LinkedIn-Logo-300dpi